Oisín Biotechnologies Publishes Preclinical Data on Muscle Gene Therapy in Cell
Oisín Biotechnologies, a private biotech firm focused on combating age-related diseases, announced the publication of preclinical data from its follistatin (FST) gene therapy program aimed at reducing muscle loss. The…
Day 2 of 11th Annual World Patient Safety Summit Focuses on Collaboration and Advanced Tech
On the second day of the 11th Annual World Patient Safety, Science & Technology Summit, hosted by the Patient Safety Movement Foundation (PSMF) at UC Irvine, the focus was on…
BeiGene Showcases TEVIMBRA® Data in Lung and GI Cancers at ESMO 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced it will present new data on TEVIMBRA® (tislelizumab) at the European Society of Medical Oncology 2024 Congress…
JuneBrain Wins MDIC Award; Chooses Compliance Group for Siemens Polarion Implementation
JuneBrain is thrilled to announce that it has received a $300,000 grant from the Medical Device Innovation Consortium’s Advanced Manufacturing Clearing House program. The funding will support the modernization of…
Doctors Opt for Contrast-Enhanced Ultrasound, Unaware of Favorable Reimbursement
Doctors are increasingly using contrast-enhanced ultrasound (CEUS) for imaging kidney masses in patients with polycystic kidney disease, often bypassing CT scans altogether due to CEUS’s effectiveness. “They go right to…
Novel TROP2 Biomarker Predicts Outcomes for Datopotamab Deruxtecan in NSCLC: TROPION-Lung01 Phase III
An exploratory analysis of the TROPION-Lung01 Phase III trial found that the TROP2 biomarker, assessed via AstraZeneca’s computational pathology platform, Quantitative Continuous Scoring (QCS), effectively predicted clinical outcomes in patients…
Daiichi Sankyo Addresses Healthcare Gaps and Unmet Needs in Cardiovascular Care
Daiichi Sankyo Europe (Daiichi Sankyo) has announced an enhanced commitment to tackling significant gaps in cardiovascular care, focusing on disparities in treatment and outcomes among different patient groups. This renewed…
Phase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS®…
Sensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris
Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris…
EDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries
EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®.…
Arrowhead Presents Phase 3 PALISADE Study Data on Plozasiran at ESC 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today the results of the Phase 3 PALISADE study evaluating investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a rare and severe genetic…
Fresenius Kabi and AABB Launch 19th Annual Blood Collectors Week
Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) have announced the start of the 19th annual Blood Collectors Week, taking place from September 1 to…